Vanda Pharmaceuticals | VNDA - Bienes





Bienes Cambio Fecha
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Heron Therapeutics USD 252.26M 6.05M 2026-06
Insmed USD 2.1B 26.7M 2026-06
J&J USD 201.06B 167M 2026-06
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Ligand Pharmaceuticals USD 2.19B 653.77M 2026-06
Merck USD 129.8B 1.12B 2026-06
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 10.96B 527M 2026-06
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 129.06B 1.04B 2026-06
Takeda JPY 15.66T 210.16B 2026-06
Teva Pharmaceutical Industries USD 39.86B 183M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Veracyte USD 1.49B 49.97M 2026-06